Literature DB >> 12007507

Pulmonary alveolar proteinosis as a terminal complication in myelodysplastic syndromes: a report of four cases detected on autopsy.

Nahoko Shoji1, Yoshikazu Ito, Yukihiko Kimura, Jiroh Nishimaki, Yuzuru Kuriyama, Tetsuzo Tauchi, Makoto Yaguchi, Dilnur Payzulla, Yoshiro Ebihara, Kazuma Ohyashiki.   

Abstract

Secondary pulmonary alveolar proteinosis (PAP) is one of the complications of hematologic malignancy and immunosuppressive diseases. We encountered four cases of myelodysplastic syndrome (MDS) associated with PAP detected on autopsy. They consisted of two refractory anemia (RA) and two patients with refractory anemia with excess blasts in transformation (RAEBt) at the time of MDS diagnosis, but all of them developed leukemic phase and were resistant to chemotherapy at the time of pulmonary episodes. Of the four MDS patients, two also had pulmonary aspergillosis. Previously, 69 patients with PAP associated with hematologic disorders have been reported, but there have been only seven cases with MDS, including our four patients. Of the 69 reported cases of PAP in hematologic malignancies, 24/63 (38%) informative patients with infection had fungal infections of the lung; 2/7 (29%) MDS cases had fungal infection. We should, therefore, pay careful attention to this possibility in cases of MDS with lung complications, including PAP, especially in patients in the leukemic phase of MDS.

Entities:  

Mesh:

Year:  2002        PMID: 12007507     DOI: 10.1016/s0145-2126(01)00178-3

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

Review 1.  The molecular basis of pulmonary alveolar proteinosis.

Authors:  Brenna Carey; Bruce C Trapnell
Journal:  Clin Immunol       Date:  2010-03-25       Impact factor: 3.969

2.  T-cell-restricted T-bet overexpression induces aberrant hematopoiesis of myeloid cells and impairs function of macrophages in the lung.

Authors:  Shoichi Iriguchi; Norihiro Kikuchi; Shin Kaneko; Emiko Noguchi; Yuko Morishima; Masashi Matsuyama; Keigyou Yoh; Satoru Takahashi; Hiromitsu Nakauchi; Yukio Ishii
Journal:  Blood       Date:  2014-10-27       Impact factor: 22.113

3.  High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease.

Authors:  A Sergeeva; Y Ono; R Rios; J J Molldrem
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

4.  Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia.

Authors:  Donald C Vinh; Smita Y Patel; Gulbu Uzel; Victoria L Anderson; Alexandra F Freeman; Kenneth N Olivier; Christine Spalding; Stephen Hughes; Stefania Pittaluga; Mark Raffeld; Lynn R Sorbara; Houda Z Elloumi; Douglas B Kuhns; Maria L Turner; Edward W Cowen; Danielle Fink; Debra Long-Priel; Amy P Hsu; Li Ding; Michelle L Paulson; Adeline R Whitney; Elizabeth P Sampaio; David M Frucht; Frank R DeLeo; Steven M Holland
Journal:  Blood       Date:  2009-12-29       Impact factor: 22.113

5.  Secondary pulmonary alveolar proteinosis: a confusing and potentially serious complication of hematologic malignancy.

Authors:  Jonathan H Chung; Sudhakar J Pipavath; David H Myerson; David Godwin
Journal:  J Thorac Imaging       Date:  2009-05       Impact factor: 3.000

6.  Clinical features of secondary pulmonary alveolar proteinosis associated with myelodysplastic syndrome: Two case reports.

Authors:  Yin Liu; Lu Lu Chen; Yu Ying Qiu; Yong Long Xiao; Hou Rong Cai
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

7.  Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome.

Authors:  Miki Hashimoto; Hidehiro Itonaga; Yasuhito Nannya; Hirokazu Taniguchi; Yuichi Fukuda; Takafumi Furumoto; Machiko Fujioka; Sachie Kasai; Masataka Taguchi; Hiroaki Taniguchi; Shinya Sato; Yasushi Sawayama; Sunao Atogami; Keisuke Iwasaki; Tomoko Hata; Hiroshi Soda; Yukiyoshi Moriuchi; Koh Nakata; Seishi Ogawa; Yasushi Miyazaki
Journal:  Intern Med       Date:  2019-12-26       Impact factor: 1.271

8.  Chronic myelomonocytic leukemia-associated pulmonary alveolar proteinosis: A case report and review of literature.

Authors:  Can Chen; Xi-Lian Huang; Da-Quan Gao; Yi-Wei Li; Shen-Xian Qian
Journal:  World J Clin Cases       Date:  2021-02-16       Impact factor: 1.337

9.  Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan.

Authors:  Haruyuki Ishii; John F Seymour; Ryushi Tazawa; Yoshikazu Inoue; Naoyuki Uchida; Aya Nishida; Yoshihito Kogure; Takeshi Saraya; Keisuke Tomii; Toshinori Takada; Yuko Itoh; Masayuki Hojo; Toshio Ichiwata; Hajime Goto; Koh Nakata
Journal:  BMC Pulm Med       Date:  2014-03-05       Impact factor: 3.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.